Business, energy, technology, markets and global industry news from Business News Today

PROGRESS

PharmaDeviceNews PROGRESS
Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.
Pharma & Biotech

Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval?

Mirum's ATEBRIOZ reduced abnormal bone volume in children aged 6 to under 12 with FOP. Can the results support FDA label expansion in 2027?

Read More